Top

Published in:

01-01-2015 | Nephrology - Review

A review of rodent models of peritoneal dialysis and its complications

Authors: Ji Wang, Shujun Liu, Hongyu Li, Jing Sun, Sijin Zhang, Xiaohong Xu, Yingying Liu, Yangwei Wang, Lining Miao

Published in: International Urology and Nephrology | Issue 1/2015

Abstract

This article reviews the available rodent models of peritoneal dialysis (PD) that have been developed over the past 20 years and the complications associated with their use. Although there are several methods used in different studies, the focus of this article is not to review or provide detailed summaries of these methods. Rather, this article reviews the most common methods of establishing a dialysis model in rodents, the assays used to observe function of the peritoneum in dialysis, and how these models are adapted to study peritonitis and peritoneal fibrosis. We compared the advantages and disadvantages of different methods, which should be helpful in studies of PD and may provide valuable data for further clinical studies.

Musi B, Braide M, Wieslander A, Rippe A, Albrektsson A, Henle T et al (2001) Very high daily intraperitoneal doses of carbonyl compounds affect the morphology, but not the exchange characteristics, of rat peritoneum. Blood Purif 19(3):286–292PubMedCrossRef

Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M et al (2004) Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 24(1):37–47PubMed

Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H et al (2004) Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 24(1):48–57PubMed

Mortier S, Faict D, Lameire NH, De Vriese AS (2005) Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 67(4):1559–1565PubMedCrossRef

Sayarlioglu H, Dogan E, Erkoc R, Ozbek H, Bayram I, Sayarlioglu M et al (2006) The effect of colchicine on the peritoneal membrane. Ren Fail 28(1):69–75PubMedCrossRef

Rippe A, Rippe C, Swärd K, Rippe B (2007) Disproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysis. Nephrol Dial Transplant 22(1):88–95PubMedCrossRef

Sun Y, Zhu F, Yu X, Nie J, Huang F, Li X et al (2009) Treatment of established peritoneal fibrosis by gene transfer of Smad7 in a rat model of peritoneal dialysis. Am J Nephrol 30(1):84–94PubMedCentralPubMedCrossRef

Nishimura H, Ikehara O, Naito T, Higuchi C, Sanaka T (2009) Evaluation of taurine as an osmotic agent for peritoneal dialysis solution. Perit Dial Int 29(2):204–216PubMed

Wang J, Jiang ZP, Su N, Fan JJ, Ruan YP, Peng WX et al (2013) The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci 14(5):10369–10382PubMedCentralPubMedCrossRef

10.

Peng W, Dou X, Hao W, Zhou Q, Tang R, Nie J et al (2013) Smad7 gene transfer attenuates angiogenesis in peritoneal dialysis rats. Nephrology (Carlton) 18(2):138–147CrossRef

11.

Xu T, Xie JY, Wang WM, Ren H, Chen N (2012) Impact of rapamycin on peritoneal fibrosis and transport function. Blood Purif 34(1):48–57PubMedCrossRef

12.

Hu W, Jiang Z, Zhang Y, Liu Q, Fan J, Luo N et al (2012) Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats. Mol Med Rep 6(1):93–99PubMed

13.

Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML et al (2011) Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 22(5):914–926PubMedCentralPubMedCrossRef

14.

Zweers MM, Splint LJ, Krediet RT, Struijk DG (2001) Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 16(3):651–654PubMedCrossRef

15.

Beelen RH, Hekking LH, Zareie M, van den Born J (2001) Rat models in peritoneal dialysis. Nephrol Dial Transplant 16(3):672–674PubMedCrossRef

16.

Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I et al (2001) Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 12(12):2775–2786PubMed

17.

Pawlaczyk K, Garcia-Lopez E, Kuzlan-Pawlaczyk M, Heimbürger O, Bergström J, Breborowicz A et al (2001) The effect of icodextrin-based solutions on peritoneal transport in rats undergoing chronic peritoneal dialysis. Perit Dial Int 21(Suppl 3):S359–S361PubMed

18.

Köksal IT, Usta MF, Akkoyunlu G, Toptaş B, Gülkesen KH, Erdogru T et al (2003) The potential role of advanced glycation end product and iNOS in chronic renal failure-related testicular dysfunction. An experimental study. Am J Nephrol 23(5):361–368PubMedCrossRef

19.

Mortier S, De Vriese AS, Leyssens A, Vanacker NJ, Faict D, Cornelissen M et al (2003) Antibiotic administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 23(4):331–338PubMed

20.

Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J (2005) Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant 20(1):189–193PubMedCrossRef

21.

Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL et al (2005) Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 25(1):58–67PubMed

22.

Zareie M, De Vriese AS, Hekking LH, ter Wee PM, Schalkwijk CG, Driesprong BA et al (2005) Immunopathological changes in a uraemic rat model for peritoneal dialysis. Nephrol Dial Transplant 20(7):1350–1361PubMedCrossRef

23.

van Westrhenen R, Aten J, Aberra M, Dragt CA, Deira G, Krediet RT (2005) Effects of inhibition of the polyol pathway during chronic peritoneal exposure to a dialysis solution. Perit Dial Int 25(Suppl 3):S18–S21PubMed

24.

Kim CD, Kwon HM, Park SH, Oh EJ, Kim MH, Choi SY et al (2007) Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model. Ther Apher Dial 11(1):56–64PubMedCrossRef

25.

van Westrhenen R, Zweers MM, Kunne C, de Waart DR, van der Wal AC, Krediet RT (2008) A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution. Perit Dial Int 28(5):487–496PubMed

26.

Schilte MN, Loureiro J, Keuning ED, ter Wee PM, Celie JW, Beelen RH et al (2009) Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int 29(1):26–35PubMed

27.

Cavallini N, Wieslander A, Braide M (2009) Substituting citrate for lactate in peritoneal dialysis fluid improves ultrafiltration in rats. Perit Dial Int 29(1):36–43PubMed

28.

Peng W, Zhou Q, Ao X, Tang R, Xiao Z (2013) Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis. Ren Fail 35(7):958–966PubMedCrossRef

29.

Xiao J, Guo J, Liu XX, Zhang XX, Li ZZ, Zhao ZZ et al (2013) Soluble Tie2 fusion protein decreases peritoneal angiogenesis in uremic rats. Mol Med Rep 8(1):267–271PubMed

30.

Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R et al (2012) Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant 27(2):548–556PubMedCrossRef

31.

Zhao ZZ, Cao Y, Liu ZS, Xiao J, Tang L, Wang P et al (2011) Effects of recombinant human endostatin on peritoneal angiogenesis in peritoneal dialysis rats. Nephrology (Carlton) 16(6):599–606CrossRef

32.

Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O (2003) Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 14(12):3205–3216PubMedCrossRef

33.

Aroeira LS, Lara-Pezzi E, Loureiro J, Aguilera A, Ramírez-Huesca M, González-Mateo G et al (2009) Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol 20(3):582–592PubMedCentralPubMedCrossRef

34.

Loureiro J, Sandoval P, del Peso G, Gónzalez-Mateo G, Fernández-Millara V, Santamaria B et al (2013) Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS ONE 8(4):e61165PubMedCentralPubMedCrossRef

35.

Loureiro J, Aguilera A, Selgas R, Sandoval P, Albar-Vizcaíno P, Pérez-Lozano ML et al (2011) Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol 22(9):1682–1695PubMedCentralPubMedCrossRef

36.

Zareie M, Keuning ED, ter Wee PM, Schalkwijk CG, Beelen RH, van den Born J (2006) Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 21(1):208–216PubMedCrossRef

37.

Bozkurt D, Taskin H, Sezak M, Biçak S, Sen S, Ok E et al (2008) Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial 24:32–38PubMed

38.

Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S et al (2001) An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 16(6):1262–1266PubMedCrossRef

39.

Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z et al (2003) Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int 23(1):14–22PubMed

40.

Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y (2004) Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 65(5):1927–1936PubMedCrossRef

41.

Hirahara I, Ogawa Y, Kusano E, Asano Y (2004) Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 19(7):1732–1741PubMedCrossRef

42.

Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K, Kinomura M et al (2007) Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 71(3):227–238PubMedCrossRef

43.

Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H et al (2008) Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol 28(4):661–668PubMedCrossRef

44.

Mondello S, Mazzon E, Di Paola R, Crisafulli C, Italiano D, Buemi M et al (2009) Erythropoietin suppresses peritoneal fibrosis in rat experimental model. Eur J Pharmacol 604(1–3):138–149PubMedCrossRef

45.

Hirose M, Nishino T, Obata Y, Nakazawa M, Nakazawa Y, Furusu A et al (2013) 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model. Perit Dial Int 33(2):132–142PubMedCentralPubMedCrossRef

46.

Ceri M, Unverdi S, Dogan M, Unverdi H, Karaca G, Kocak G et al (2012) Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model. Int Urol Nephrol 44(3):977–982PubMedCrossRef

47.

Kokubo S, Sakai N, Furuichi K, Toyama T, Kitajima S, Okumura T et al (2012) Activation of p38 mitogen-activated protein kinase promotes peritoneal fibrosis by regulating fibrocytes. Perit Dial Int 32(1):10–19PubMedCentralPubMedCrossRef

48.

Gotloib L, Wajsbrot V, Cuperman Y, Shostak A (2004) Acute oxidative stress induces peritoneal hyperpermeability, mesothelial loss, and fibrosis. J Lab Clin Med 143(1):31–40PubMedCrossRef

49.

Yang CY, Chau YP, Lee HT, Kuo HY, Lee OK, Yang AH (2013) Cannabinoid receptors as therapeutic targets for dialysis-induced peritoneal fibrosis. Am J Nephrol 37(1):50–58PubMedCrossRef

50.

Hoff CM (2005) Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 25(Suppl 4):S57–S66PubMed

51.

Nishimura H, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S et al (2008) Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol 294(5):F1084–F1093

52.

Mizuno M, Ito Y, Mizuno T, Harris CL, Suzuki Y, Okada N et al (2012) Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. Am J Physiol 302(10):F1245–F1251

53.

Kato H, Mizuno T, Mizuno M, Sawai A, Suzuki Y, Kinashi H et al (2012) Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model. Nephrol Dial Transplant 27(2):526–536PubMedCrossRef

54.

Li S, Zhou Y, Fan J, Cao S, Cao T, Huang F et al (2011) Heat Shock Protein 72 Enhances Autophagy as a protective mechanism in lipopolysaccharide-induced peritonitis in rats. Am J Pathol 179(6):2822–2834PubMedCentralPubMedCrossRef

55.

Leu TH, Charoenfuprasert S, Yen CK, Fan CW, Maa MC (2006) Lipopolysaccharide-induced c-Src expression plays a role in nitric oxide and TNFalpha secretion in macrophages. Mol Immunol 43:308–316PubMedCrossRef

56.

Song SH, Kwak IS, Yang BY, Lee DW, Lee SB, Lee MY (2009) Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model. Nephrology (Carlton) 14:155–163CrossRef

57.

Cao S, Li S, Li H, Xiong L, Zhou Y, Fan J et al (2013) The potential role of HMGB1 release in peritoneal dialysis-related peritonitis. PLoS ONE 8(1):e54647PubMedCentralPubMedCrossRef

58.

Ni J, McLoughlin RM, Brodovitch A, Moulin P, Brouckaert P, Casadei B et al (2010) Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant 25(1):86–96PubMedCentralPubMedCrossRef

59.

Ni J, Cnops Y, McLoughlin RM, Topley N, Devuyst O (2005) Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int 25(Suppl 3):S11–S14PubMed

60.

Cavanagh JP, Granslo HN, Fredheim EA, Christophersen L, Jensen PØ, Thomsen K, Van Gennip M et al (2013) Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model. J Antimicrob Chemother 68(9):2106–2110PubMedCrossRef

61.

Aoyama T, Ogata K, Shimizu M, Hatta S, Masuhara K, Shima Y et al (2005) Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Drug Metab Pharmacokinet 20(6):485–490PubMedCrossRef

62.

van Westrhenen R, Westra WM, van den Born J, Krediet RT, Keuning ED, Hiralall J et al (2006) Alpha-2-macroglobulin and albumin are useful serum proteins to detect subclinical peritonitis in the rat. Perit Dial Int 26(1):101–107PubMed

63.

Ersoy R, Celik A, Yilmaz O, Sarioglu S, Sis B, Akan P et al (2007) The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 27(4):424–431PubMed

64.

Park MS, Heimbürger O, Bergström J, Waniewski J, Werynski A, Lindholm B (1994) Evaluation of a rat model of peritoneal dialysis: fluid and solute transport characteristics. Nephrol Dial Transplant 9:404–412PubMed

65.

Park MS, Heimbürger O, Waniewski J, Werynski A, Lee HB, Bergström J et al (1995) The effect of dialysate acidity on peritoneal solute transport in the rat. Perit Dial Int 15(8):312–319PubMed

66.

Wang T, Heimbürger O, Cheng HH, Bergström J, Lindholm B (1998) Peritoneal fluid and solute transport with different polyglucose formulations. Perit Dial Int 18(2):193–203PubMed

67.

Park MS, Lee EY, Lee NS, Waniewski J, Lindholm B, Lee HB (1998) The effects of ouabain and potassium on peritoneal fluid and solute transport characteristics. Perit Dial Int 18(4):402–409PubMed

68.

Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimbürger O, Bergström J, Waniewski J et al (2001) Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 16(3):669–671PubMedCrossRef

69.

Park MS, Lee EY, Suh GI, Waniewski J, Werynski A, Lee HB (1999) Peritoneal transport of glucose in rat. Perit Dial Int 19(5):442–450PubMed

70.

Van Biesen W, De Vriese AS, Carlsson O, Van Landschoot M, Dheuvaert T, Lameire NH (2002) Comparison of the radioiodinated serum albumin (RISA) dilution technique with direct volumetric measurements in animal models of peritoneal dialysis. Perit Dial Int 22(3):316–322PubMed

71.

Lindholm B, Werynski A, Bergström J (1987) Kinetics of peritoneal dialysis with glycerol and glucose as osmotic agents. Trans Am Soc Artif Intern Organs 33:19–27

72.

Lee JH, Reddy DK, Saran R, Moore HL, Twardowski ZJ, Nolph KD et al (2000) Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 20(6):643–651PubMed

73.

Zeltzer E, Klein O, Rashid G, Katz D, Korzets Z, Bernheim J (2000) Intraperitoneal infusion of glucose-based dialysate in the rat–an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport. Perit Dial Int 20(6):656–661PubMed

74.

Wieczorowska-Tobis K, Polubinska A, Wisniewska J, Pawlaczyk K, Kuzlan-Pawlaczyk M, Filas V et al (2001) Multidirectional approach to study peritoneal dialysis fluid biocompatibility in a chronic peritoneal dialysis model in the rat. Nephrol Dial Transplant 16(3):655–656PubMedCrossRef

75.

Duman S, Günal AI, Sen S, Asçi G, Ozkahya M, Terzioglu E et al (2001) Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 21(2):219–224PubMed

76.

Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL (2004) Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 24(2):115–122PubMed

77.

Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M et al (2005) Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 68(3):1326–1336PubMedCrossRef

78.

Shin SK, Kamerath CD, Gilson JF, Leypoldt JK (2006) Effects of anaesthesia on fluid and solute transport in a C57BL6 mouse model of peritoneal dialysis. Nephrol Dial Transplant 21(10):2874–2880PubMedCrossRef

79.

Yuan J, Fang W, Ni Z, Dai H, Lin A, Cao L et al (2009) Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2. Pediatr Nephrol 24(1):163–170PubMedCrossRef

80.

Song SH, Kwak IS, Yang BY, Lee DW, Lee SB, Lee MY (2009) Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model. Nephrology (Carlton) 14(2):155–163CrossRef

81.

Mendelson AA, Guan Q, Chafeeva I, da Roza GA, Kizhakkedathu JN, Du C (2013) Hyperbranched polyglycerol is an efficacious and biocompatible novel osmotic agent in a rodent model of peritoneal dialysis. Perit Dial Int 33(1):15–27PubMedCentralPubMedCrossRef

82.

Bui DS, Seguro AC, Shimitzu MH, Schliemann I, Martini D, Romão JE Jr et al (2012) N-Acetylcysteine protects the peritoneum from the injury induced by hypertonic dialysis solution. J Nephrol 25(1):90–95PubMedCrossRef

83.

Ni J, Cnops Y, Debaix H, Boisdé I, Verbavatz JM, Devuyst O (2005) Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int 67(5):2021–2031PubMedCrossRef

Title: A review of rodent models of peritoneal dialysis and its complications
Authors: Ji Wang
Shujun Liu
Hongyu Li
Jing Sun
Sijin Zhang
Xiaohong Xu
Yingying Liu
Yangwei Wang
Lining Miao
Publication date: 01-01-2015
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 1/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-014-0829-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

UVA-photoactivated riboflavin effect on isolated vaginal tissues derived from pelvic organ prolapse cases

Correction of metabolic acidosis in hemodialysis: consequences on serum leptin and mineral metabolism

The alteration of inflammatory markers and apoptosis on chronic prostatitis induced by estrogen and androgen

From ureteric bud to the first glomeruli: genes, mediators, kidney alterations

Can a four-session biofeedback regimen be used effectively for treating children with dysfunctional voiding?

Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage